Antigen-presenting cells such as dendritic cells (DCs) play a critical role in inducing and regulating immune responses. One effective strategy for DC-based immunotherapy is to regulate maturation and function of DC. In this study, we apply single-walled carbon nanotubes (SWNTs) to carry small interfering RNA (siRNA) to reach, enter and genetically modify DCs in vivo. We prepared positively charged SWNTs (SWNTs+) using 1,6-diaminohexane which was demonstrated by transmission electron microscopy equipped with energy-dispersive X-ray spectroscopy and atomic force microscope. The functionalized SWNTs+ could absorb siRNA to form complexes of siRNA with SWNTs. These siRNA:SWNT+ complexes were preferentially taken up by splenic CD11c+ DCs, CD11b+ cells and also Gr-1+CD11b+ cells comprising DCs, macrophages and other myeloid cells to silence the targeting gene. Suppressor of cytokine signaling 1 (SOCS1) restricts the ability of DCs to break self-tolerance and induce antitumor immunity. Infusion of SWNTs+ carrying SOCS1siRNA reduced SOCS1 expression and retarded the growth of established B16 tumor in mice, indicating the possibility of in vivo immunotherapeutics using SWNTs-based siRNA transfer system.
Introduction
RNA interference (RNAi) is a powerful tool to dissect the functional consequences of target inactivation in mammalian cells and model organisms. 1 The potency and specificity of RNAi are appealing for therapeutic intervention strategies. 1, 2 RNAi is mediated by small interfering RNAs (siRNAs) produced from long doublestranded RNAs (dsRNAs) of exogenous or endogenous origin by an endonuclease called dicer. 1 siRNAs comprise duplexes of 21 nt dsRNAs with 19 bp and 2 nt, 3 0 overhanging ends. siRNA engages in sequence-specific interactions to inhibit gene expression by RNA degradation. A critical requirement for achieving safe and efficacious siRNA therapeutics is the introduction of 'drug-like' properties. In vivo delivery of siRNAs to target cells is also hampered by siRNA stability, low uptake efficiency and properties of their biodistribution and pharmacokinetics. 3 Chemically stabilized siRNAs showed significantly enhanced resistance against degradation by exo-and endonucleases and maintenance of biological activity. 4 However, delivery of synthetic siRNAs to certain cell types, for example, dendritic cells (DCs), is hampered by limitations in transfection efficiency. 3 Thus, although siRNA has great promise as a tool to address basic biological questions and therapeutic strategies, better siRNA delivery is necessary to realize this potential.
The unique properties of single-walled carbon nanotubes (SWNTs) suggest a plethora of potential applications. Functionalized SWNTs are attracting increasing attention as new vectors for the delivery of therapeutic molecules. Oxidized SWNTs can be functionalized at their carboxylic groups with proteins, 5 peptide, 6 peptide nucleic acid, 7 oligonuceotide, 8 sugar moieties 9 and poly oxide derivatives. 10 The functionalized SWNTs can shuttle these molecular cargoes into mammalian cells, indicating their potential application as transporters. Dai et al. 11 recently reported that functionalized SWNTs can transport siRNA into mammalian cells and silence the targeted gene. SWNTs can also deliver oligonucleotides to the nucleus. 11 Thus, functionalized SWNTs carrying genetic molecules such as siRNA or antisense DNA oligonucleotides have promise for gene therapy and gene interference.
DCs are the most efficient antigen-presenting cells and central to the development of effective immunity. DCs encompass a variety of subpopulations including immature DCs (imDCs), mature dendritic cells (mDCs) and several other sub-populations defined on the basis of surface markers, functional potential and location. 12, 13 DCs play a critical role in priming adaptive immunity and orchestrating immune responses against pathogens and tumors. 12 The regulatory function of DCs is strictly dependent on their stage of maturation and activation state. DCs maturation is associated with cytokine production and increased surface expression of major histocompatibility complex II and costimulatory molecules such as CD80 that regulate the outcome of antigen presentation. One reason for the failure of antitumor immunotherapy is believed to be the presence of immunosuppressive mechanisms controlled by intracellular signaling system in DCs. Suppressor of cytokine signaling 1 (SOCS1), a negative regulator of signaling can inhibit the Janus kinase to block cytokine signal transduction.
14 Ex vivo silencing of the intracellular signal regulator SOCS1 in antigen-presenting cell DCs strongly enhances antigen-specific antitumor immunity, 15 and represents a promising approach to trigger tumor rejection.
DCs, especially imDCs can capture and engulf antigens via phagocytosis. Because both endocytosis and phagocytosis are the primary mechanisms of penetration of SWNTs into cells, we hypothesized that intravenously (i.v.) delivered SWNTs would be engulfed by antigenpresenting cells. Herein, we examine i.v. delivery of siRNA:SWNTs+ complexes targeting CD80 and SOCS1, to assess their potential to modulate DCs function and tumor rejection in mice.
Results

Uptake of the functionalized SWNTs by DCs
Although prior studies have described the penetration of functionalized SWNTs into several different cell types, their uptake by DCs has not been tested. Thus, we prepared FAM-labeled DNA-functionalized SWNTs to assess entry into DCs. The FAM-labeled DNA-functionalized SWNTs were examined by transmission electron microscopy (TEM, Figure 1A ) and atomic force microscope (AFM, Figure 1B) . The fluorescence spectra of DNA-functionalized SWNTs hybridized with complement DNA (c-DNA: 5 0 -TGC-ATT-TTT-AAT-GGT-ATT-TA-3 0 -FAM) showed stronger fluorescence at 516 nm than when incubated with non-complement DNA (n-DNA: Figure 1C ), further indicating that conjugation of functionalized SWNTs with c-DNA had occurred. We also produced mouse bone marrow-derived dendritic cells (BMDCs), including immature dendritic cells (imBMDCs) and mature dendritic cells (mBMDCs), by standard procedures. Compared to imBMDCs, mBMDCs expressed high level of CD40, CD80 and CD86 costimulatory molecules and exhibited the typical mor- SWNTs-mediated delivery of siRNA into antigen-presenting cells R Yang et al phology of mDCs ( Figure 1D ). FAM-labeled DNAfunctionalized SWNTs could enter into both imBMDCs and mBMDCs, although uptake by mBMDCs was significantly lower than by imBMDCs ( Figure 1E ). As a control, FAM-labeled DNA fragments alone did not enter into these DCs ( Figure 1E ). Consistent with other reports, 16 FAM-labeled DNA-functionalized SWNTs also penetrated other mammalian cell lines including RAW264.7 (data not shown).
Uptake of functionalized SWNTs by splenic CD11C+ DCs in vivo
Phagocytosis is the typical mechanism by which functionalized SWNTs enter into the cells. Indeed, the known reduction in phagocytosis by mBMDCs as compared to imBMDCs correlated with reduced uptake of functionalized SWNTs ( Figure 1E ). We thus hypothesized that SWNTs-dsDNA-FAM might be preferentially engulfed in vivo by antigen-presenting cells, which possess phagocytic potential, such as imDCs and macrophages. As shown in Figure 2A , i.v. injected SWNTs-dsDNA-FAM were predominantly taken up by larger size splenic cells ( Figure 2A ) comprising mainly monocyte/macrophages, imDCs and mDCs; whereas the smaller cell population which represents mostly T and B cells did not show strong predominant uptake of SWNTs (Figure 2A ). Further phenotypic analysis revealed that SWNTsdsDNA-FAM complexes were taken up by splenic CD11c+ DCs ( Figure 2B ). Similar uptake by CD11b+ cells was also found, indicating the involvement of macrophages. Whereas most of B220+, CD4+ or CD8a+ splenic cells did not take up SWNTs-dsDNA-FAM, a minor fraction of B220+, CD4+ or CD8+ cells exhibited remarkably efficient uptake of SWNTs-dsDNA-FAM complexes ( Figure 2B ). As there are several murine splenic DC subsets, which express not only CD11c and CD11b but also CD4, CD8a or CD4CD8a and/or B220 molecules, 17 SWNTs-mediated delivery of siRNA into antigen-presenting cells R Yang et al RAW264.7 cells using the GenePorter reagent (data not shown). To prepare the CD80siRNA:SWNT complexes, we first functionalized SWNTs with -CONH-(CH 2 ) 6 -NH 3 + Á Cl À group to make positively charged SWNTs with a strong affinity for siRNA. Functionalization of SWNTs with -CONH-(CH 2 ) 6 -NH 3 + Á Cl À was clearly shown by the appearance of new peaks at B2923 cm À1 (C-H) and B1401 cm À1 (C-C) and the bands at 1713 cm À1 and 1632 cm À1 assigned to amide band (C ¼ O) ( Figure 3 ). As shown in Figure 3A , -CONH-(CH 2 ) 6 -NH 3 + Á Cl À promoted the coupling of siRNA to oxidized SWNTs. Conjugation of siRNA to oxidized SWNTs was demonstrated by TEM equipped with energy-dispersive X-ray spectroscopy (EDS) ( Figure 3B ) and spectrophotometry at the wavelength 260 nm ( Figure 3C ). The EDS spectrum of siRNA:SWNTs+ complex exhibited a strong peak for phosphorus element, whereas this phosphorus element peak is absent in the siRNA:SWNTs suggesting the failure of the latter to couple efficiently ( Figure 3B ). The coupling of siRNA and SWNTs+ could also be observed under TEM ( Figure 3D1 ) and AFM ( Figure 3D2 ).
When the CD80siRNA:SWNTs+ were incubated with imDCs and mDCs, both clearly showed reduced surface CD80 expression ( Figure 4A3 and B3). Specific inhibition was also demonstrated at the transcript level ( Figure 4D ). Similarly, CD80siRNA:SWNTs+ also reduced the expression of CD80 on the surface of RAW264.7 and the level of mRNA ( Figure 4C and D) . As control, SWNTs+ incubated with mocksiRNA did not induce CD80 gene silencing ( Figure 4A2 , B2 and C2). Although naked siRNA may transfect DCs after long incubation periods, 18 naked siRNA alone was not sufficient to cause significant CD80 RNAi in the limited time of this assay ( Figure 4A1 , B1 and C1). CD80siRNA:SWNTs+ also failed to affect transcripts of the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
We next assessed whether in vivo injection of CD80siRNA:SWNT+ complexes could also silence CD80 gene expression in antigen-presenting cells. Consistent with the in vivo cellular distribution of FAMlabeled functionalized SWNTs, mouse CD80siR-NA:SWNTs+ complexes reduced the surface expression of CD80 in the CD11c+ DC and CD11b+ macrophage subsets when injected into the tail vein of mice ( Figure  4E ). No remarkable changes were observed in the expression of CD80 on the surface of DCs in mice injected with SWNTs, CD80siRNA alone or mocksiRNA: SWNTs+ complexes ( Figure 4E ).
SWNTs-mediated in vivo delivery of siRNA into tumor-associated Gr-1+CD11b+ cells
To further explore the uptake of siRNA:SWNTs+ by antigen-presenting cells, we also examined myeloid immunosuppressive cells (MSCs), 19 often found in tumor-bearing humans and mice. As MSCs dampen antitumor immune responses, they represent an impor- SWNTs-mediated delivery of siRNA into antigen-presenting cells R Yang et al tant potential target for genetic therapy. These cells can be identified in mice by expression of CD11b, Gr-1 and markers such as CD80. Gr-1+CD11b+ cells represent a heterogeneous population of myeloid cells comprising immature macrophages, DCs and other myeloid cells at earlier stages of differentiation. 20 Because most of these cells have potential to engulf siRNA:SWNT+ complexes and express CD80, as a proof-of-principle we explored the activity of CD80siRNA:SWNTs+ in MSCs after i.v. administration in mice bearing tumor. When CD80siRNA: SWNT+ complexes were injected into the tail vein of mice bearing Lewis lung carcinoma (LLC) tumor, Gr-1+CD11b+ cells isolated from the spleen of these mice exhibited a reduced CD80 expression, whereas injection of CD80siRNA alone or SWNT+ with mocksiRNA did not alter the expression of CD80 in the same cellular population ( Figure 5A ). This suggests that CD80siRNA: SWNT+ complexes were not only taken up by these tumor-associated Gr-1+CD11b+ cells but also provided specific RNAi ( Figure 5A ). The uptake by MSCs of the functionalized SWNTs-dsDNA-FAM after i.v. injection was also demonstrated ( Figure 5B ). In vitro incubation of Gr-1+CD11b+ cells with CD80siRNA:SWNT+ complexes also reduced expression of CD80 ( Figure 5C ) suggesting that the CD80 RNAi was a direct effect upon this cell type.
SOCS1siRNA:SWNTs are capable of inhibiting pre-established B16 tumors
The ability of siRNA:SWNT+ complexes to produce RNAi in antigen-presenting cells including Gr1+CD11b+ cells suggests possible utility for tumor immunotherapy. As CD80 expression by DCs contributes to the induction of immunity, we selected an alternate target, the intracellular signal regulator SOCS1, to test SWNTs-mediated delivery of siRNA into antigen-presenting cells R Yang et al the applicability of siRNA:SWNT+ complexes for tumor immunotherapy by in vivo RNAi. SOCS1 was selected for ex vivo silencing of SOCS1 in antigen-presenting cells; DCs strongly enhances antigen-specific antitumor immunity. 15 The selected SOCS1siRNA:SWNT complexes reduced the expression level of SOCS1 transcripts and protein in BMDCs as demonstrated by reverse transcriptase-polymerase chain reaction (RT-PCR) (Figure 6a ) and Western blotting (Figure 6b ) in vitro. To determine whether SOCS1 knockdown in DCs provided a functional benefit, we compared the efficiency of ovalbumin (OVA) peptide presentation by imBMDCs treated with SOCS1siRNA:SWNT+ complexes, mocksiRNA:SWNT+ complexes, or siRNA alone. After lipopolysaccharide (LPS) (1 mg/ml) stimulation, these DCs were loaded with OVA peptide (Siinfekl, 10 mg/ml) and then added into OVA-specific splenic cells. The supernatants were collected and presence of interferon-g (IFN-g) was determined. Notably, SOCS1 knockdown with SOCS1-siRNA:SWNT+ complexes significantly improved the antigen-presenting function of DCs (Figure 6c ), indicating that SWNTs carry complexed siRNA into DCs wherein they release the siRNA from the nanotube sidewalls to silence the targeted gene. The functionalized SWNTs may represent a new class of molecular transporters applicable for siRNA therapeutics.
Notably, siRNA:SWNTs+ did not impact the phenotype and morphology of DCs (data not shown), implying no effect of siRNA:SWNT+ complexes on DCs differentiation and function. Indeed, even at 0.05 mg/ml 
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SWNTs and incubation for 5 days, no appreciable cell death was observed compared to control (data not shown). Given the ability of SOCS1siRNA:SWNTs+ to produce SOCS1 RNAi and promote antigen presentation by DCs in vitro, we explored their effect in vivo upon B16 tumor growth. Intravenous injection of SOCS1siRNA SWNTs+ significantly retarded tumor growth after 15 days (Po0.05) (Figure 6d ), whereas siRNA alone or mocksiRNA:SWNTs+ had no significant effect with respect to the control.
Discussion
The potency and specificity of RNAi suggest many potential clinical applications, but the success of this approach is dependent upon an efficient system for delivery of the therapeutic siRNA in the target organ or tissue. To this end, both viral and non-viral vectors are currently being tested. Although viral gene delivery can effectively deliver siRNA, viral vectors can be immunogenic, or induce inflammation and potentially have oncogenic effects. 21 Carriers such as liposomes are well documented, 22 but fail to protect siRNA from degradation and control release. SWNTs have been shown to shuttle various cargoes across cell membranes without toxicity, suggesting potential for drug, protein and gene delivery applications. Indeed, ammonium-functionalized SWNTs penetrate human and murine cells and facilitate the delivery of plasmid DNA leading to expression of marker genes. 16 In this study, we demonstrate that positively charged SWNTs also represent an effective transporter for siRNA to phagocytic cells including DCs, macrophages and MSCs in vivo. However, important questions as to the bioavailability, metabolism and long-term effects of SWNTs in patients remain to be addressed.
Numerous techniques have been designed to optimize DCs activation and induction of tumor-specific immune responses in vivo. The concept of inhibiting the inhibitor to potentiate antitumor immunity was pioneered by Shen et al. 15 who provided the first example of interfering with a negative regulatory pathway in DCs to enhance their immunostimulatory capacity. The importance of negative regulation in attenuation of DCs maturation and function in adaptive immunity is clear. 23 For example, immune manipulation of DCs during ballistic SWNTs-mediated delivery of siRNA into antigen-presenting cells R Yang et al vaccination with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging DCs life. 24 Likewise, siRNA-mediated knockdown of SOCS1 enhances the immunostimulatory capacity of DCs and leads to more effective cancer vaccination. 15 imDCs are highly phagocytic and efficiently internalize siRNA: SWNTs+ after i.v. injection. As our understanding of the contribution of DC-negative regulatory mechanisms, the potential to influence adaptive immunity and tumor tolerance by regulation of DCs function through i.v. delivery of siRNA:SWNTs+ is great.
Materials and methods
Preparation of SWNTs DNA labeled with FAM fluorescein (SWNTs-dsDNA-FAM)
SWNTs-dsDNA-FAM complexes were prepared as described previously. 25 The SWNTs were purified, shortened and functionalized with FAM-labeled DNA (Shanghai Sangon Biological Engineering Technology & Services CO., Ltd, Shanghai, China) according to Hazani et al. 26 Briefly, shortened SWNTs (s-SWNTs) (0.5 mg) were sonicated in 5 ml Triton-X suspension in the presence of 2-morpholinoethanesulfonic acid monohydrate (Aldrich, St Louis, MO, USA) (100 mM, pH 6.0), 1-ethyl-3 (3-dimethy amino-propyl) carbodiimide (100 mM) (Aldrich) and N-hydroxy succinimide (100 mM) (Aldrich) for 1 h at room temperature to form a labile intermediate and then the pH was raised to 8.5. Amino-modified oligonucleotides (5 mM) (5 0 -TAA-ATA-CCA-TTA-AAA-ATG-CA -(CH 2 ) 6 -NH 2 -3 0 ; Shanghai Sangon Biological Engineering Technology & Services CO., Ltd ) were added to form an amide linkage between the primary amine located at the 3 0 of the captured oligonucleotide and the carboxylic acid groups on the SWNTs to produce SWNTs functionalized with single strand DNA (SWNTs-sDNA). The SWNTsDNA was washed with deionized water and characterized using EDS (FEI, and AFM (Veeco Nanoscope, Woodbury, NY, USA, multimode scanning probe microscope). SWNTs-sDNA (50 mg/l) and the target DNA labeled with FAM (27 mM) were mixed in boiling water and then cooled to 41C to permit annealing and the resulting functionalized SWNTs-dsDNA-FAM was washed before use. SWNT-sDNA hybridized with c-DNA or n-DNA labeled with FAM was assayed using fluorescence spectroscopy (Jobin Yvon, FluoroMax-P, Edison, NJ, USA).
siRNA design, synthesis and transfection
The siRNA sequences used for gene silencing of murine CD80 and SOCS1 were designed according to the protocol on http://www.ambion.com. The two CD80 sequences targeted were AACTGTCCAAGTCAGT GAAAG (sequence no. To prepare positively charged SWNTs (SWNTs+) we first generated the tert-butyl N-(6-aminohexyl) carbamate (Boc-C 6 H 12 NH 2 ) using a procedure reported by Far et al. 27 SWNT-COCl was prepared from s-SWNTs based on the reported method. 28 SWNT-COCl (0.0691 g) and Boc-C 6 H 12 NH 2 (4.3 g) were then reacted in dimethylformamide at 9001C for 96 h under argon. 29 This procedure avoids reaction of amino groups of 1,6-diaminohexane between SWNTs and consequent aggregation. SWNTs functionalized by this procedure form a stable homogenous suspension and better disperse in water than SWNTs prepared by conventional methods.
In vitro transfection and in vivo distribution of siRNA:SWNT+ complexes
To prepare siRNA-functionalized SWNTs, SWNT-CONH-(CH 2 ) 6 -NH 3 + (50-100 mg/l) were incubated with siRNA at 100 nM for 1 h at room temperature and then washed twice before use. The coupling of siRNA to SWNTs+ was characterized by TEM equipped with EDS, AFM and spectrophotometry (Eppendorf, Biophotometer).
The siRNA:SWNTs+ preparations were used to transfect DCs, the monocyte/macrophage cell line RAW264.7 and Gr-1+CD11b+ cells. The cells first were cultured in 24-well plates in RPMI1640 medium supplemented with 10% fetal calf serum (FCS) and 1% penicillin/ streptomycin. These cells were transfected using siRNA:SWNT+ complexes at a concentration of 2 nM siRNA for 24 h. The level of CD80 mRNA was detected by RT-PCR. The surface expression of CD80 was analyzed using flow cytometry after 48 h.
CD80siRNA:SWNT+ complexes were injected into the tail vein of mice using 100 ml 2 nM siRNA (CD80siRNA: SWNT+ complexes). Control mice were injected using 100 ml 2 nM CD80siRNA or 100 ml 2 nM control siRNA: SWNT+ complex. The spleen cells from six mice per group were collected and analyzed by flow cytometry.
Tumor models
To determine the uptake of SWNTs by immunosuppressive cells, we set up mouse model of LLC. Two million LLC cells were injected subcutaneously (s.c.) into the right flank of syngeneic C57BL/6 mice. As described for other murine tumors, 16, 30 an accumulation of immunosuppressive Gr-1+CD11b+ cells could be found in these mice after 5 weeks.
LLC and B16 tumor cells are obtained from the Beijing and Animal Center (Beijing, PRC) and ATCC (Manassas, SWNTs-mediated delivery of siRNA into antigen-presenting cells R Yang et al VA, USA) respectively. B16 tumor cells (1 Â 10 6 ) were injected s.c. into the right flank of syngeneic C57BL/6 mice. On the day after tumor inoculation, the mice were randomly divided into five groups (n ¼ 6/group) and groups were injected with 100 ml of SOCS1siRNA:SWNT complexes (2 nM siRNA), control siRNA:SWNTs complexes (2 nM siRNA), siRNA alone (2 nM siRNA) or phosphate-buffered saline (PBS).
DCs, antibodies and flow cytometric analysis
Mouse BMDCs were prepared as described previously. 17, 31 Day 4 DCs were used as imDCs and day 9 DCs were converted to mDCs by giving CpG (100 nM/ ml) stimulation in medium containing 1000 U/ml granulocyte macrophage colony-stimulating factor for 24 h. Monocyte/marophage cell line Raw264.7 cells (ATCC, Manassas, VA, USA) were grown in the RPMI-1640 medium supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. To determine penetration of SWNTs, 100 ml of the cell suspension (1 Â 10 6 ) was mixed with 10 ml of SWNTs-dsDNA-FAM at 371C for 3 h in 5% CO 2 atmosphere.
To assess surface marker phenotypes of BMDCs, the cells were collected in ice-cold PBS and incubated with the following antibodies: fluorescein isothiocyanate-conjugated anti-CD11c (N418), anti-mouse CD86 (GL1), antimouse CD80 (16-10A1), anti-mouse CD40 (3/23) and PE-labeled anti-mouse CD45 R/B220 (RA36B2), antimouse CD11b (M1/70), CD4 (L3T4) and CD8a (Ly-2). All these antibodies were purchased from PharMingen (Rockville, MD, USA). Cells were then washed twice and resuspended in PBS/1% paraformadehyde/1% FCS and kept at 41C before flow cytometric analysis (FACScan, Becton Dickson, Franklin Lakes, NJ, USA). To assess the effects of SWNTs on the cellular viability, cells were incubated with different concentrations of SWNTs for 5 days and then analyzed by flow cytometry after propidium iodide staining. For each analysis, isotypematched control monoclonal antibody was used as a negative control.
RT-PCR analysis
Total cellular RNA was prepared using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) followed by RNA clean up using an RNeasy Mini kit (Qiagen, Valencia, CA, USA). RT-PCR was performed using SuperScript onestep RT-PCR with Platinum Taq according to the protocol provided (Invitrogen). Amplification conditions included cDNA synthesis and pre-denaturation: one cycle (501C for 15 min, 941C for 2 min); PCR amplification for 40 cycles (denature, 941C for 15 s; anneal, 551C for 30 s; extend 721C for 1 min/kb) and final extension: one cycle (721C for 10 min). The primers used were: mouse CD80: 5 0 -atggcttgcaattgtcagttgatgcagg and 3 0 -ctaaaggaa gacggtctg; mouse SOCS1: 5 0 -atggtagcacgcaaccagg and 3 0 -gaaggggaaggtctagact; GAPDH: 5 0 -atggtgaaggtcggtgt gaacggatttggc and 3 0 -catcgaaggtggaagagtgggagttgctgt.
Western blotting analysis
For Western blot analysis, mBMDCs were transfected by SOCS1mRNA:SWNT+ complexes. The cells were harvested 48 h later and subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Following transfer to Hybond-P membrane (Amersham, Piscataway, NJ, USA), the samples were analyzed by Western blotting with anti-SOCS1 antibody (AnaSpec, San Jose, CA, USA) and actin antibody (Santa Cruz, CA, USA). The protein-antibody complexes were detected using the peroxidase-conjugated secondary antibody (Boehringer Mannheim, Indianapolis, IN, USA) and enhanced chemiluminescence (Amersham).
Statistical analysis
For statistical analysis, we used Student's t-test, and a 95% confidence limit was taken to be significant, defined as Po0.05. Results are presented as means7s.e.
